Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB. Reich K, et al. Among authors: la rosa c. Lancet. 2017 Jul 15;390(10091):276-288. doi: 10.1016/S0140-6736(17)31279-5. Epub 2017 Jun 6. Lancet. 2017. PMID: 28596043 Clinical Trial.
Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
Papp KA, Reich K, Blauvelt A, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaci D, Li Q, Cichanowitz N, Green S, La Rosa C. Papp KA, et al. Among authors: la rosa c. J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1098-1106. doi: 10.1111/jdv.15400. Epub 2019 Mar 5. J Eur Acad Dermatol Venereol. 2019. PMID: 30838709
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
Kimball AB, Papp KA, Reich K, Gooderham M, Li Q, Cichanowitz N, La Rosa C, Blauvelt A. Kimball AB, et al. Among authors: la rosa c. Br J Dermatol. 2020 Jun;182(6):1359-1368. doi: 10.1111/bjd.18484. Epub 2019 Nov 19. Br J Dermatol. 2020. PMID: 31487406 Free PMC article. Clinical Trial.
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
Smith JA, Birring SS, Dicpinigaitis PV, McGarvey LP, Morice AH, Pavord ID, Satia I, Green S, Iskold B, La Rosa C, Li Q, Martin Nguyen A, Schelfhout J, Muccino D. Smith JA, et al. Among authors: la rosa c. Lung. 2022 Aug;200(4):423-429. doi: 10.1007/s00408-022-00553-y. Epub 2022 Jul 27. Lung. 2022. PMID: 35895098 Free PMC article. Clinical Trial.
Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough.
Dicpinigaitis PV, Birring SS, Blaiss M, McGarvey LP, Morice AH, Pavord ID, Satia I, Smith JA, La Rosa C, Li Q, Nguyen AM, Schelfhout J, Tzontcheva A, Muccino D. Dicpinigaitis PV, et al. Among authors: la rosa c. Ann Allergy Asthma Immunol. 2023 Jan;130(1):60-66. doi: 10.1016/j.anai.2022.05.003. Epub 2022 May 13. Ann Allergy Asthma Immunol. 2023. PMID: 35569802
A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
Niimi A, Sagara H, Kikuchi M, Arano I, Sato A, Shirakawa M, La Rosa C, Muccino D. Niimi A, et al. Among authors: la rosa c. Allergol Int. 2022 Oct;71(4):498-504. doi: 10.1016/j.alit.2022.05.006. Epub 2022 Jun 23. Allergol Int. 2022. PMID: 35752582 Free article. Clinical Trial.
Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks.
Birring SS, Dicpinigaitis PV, Smith JA, Morice AH, McGarvey LP, Pavord ID, Nguyen AM, Schelfhout J, Li Q, Iskold B, Green SA, Philip G, Muccino DR, La Rosa C. Birring SS, et al. Among authors: la rosa c. Am J Respir Crit Care Med. 2023 Jun 1;207(11):1539-1542. doi: 10.1164/rccm.202211-2128LE. Am J Respir Crit Care Med. 2023. PMID: 36996347 Free PMC article. No abstract available.
Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial.
Birring SS, Cardozo L, Dmochowski R, Dicpinigaitis P, Afzal A, La Rosa C, Lu S, Nguyen AM, Yao R, Reyfman PA. Birring SS, et al. Among authors: la rosa c. Lancet Respir Med. 2024 Nov;12(11):855-864. doi: 10.1016/S2213-2600(24)00222-4. Epub 2024 Aug 30. Lancet Respir Med. 2024. PMID: 39222649 Clinical Trial.
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
Muccino DR, Morice AH, Birring SS, Dicpinigaitis PV, Pavord ID, Assaid C, Kleijn HJ, Hussain A, La Rosa C, McGarvey L, Smith JA. Muccino DR, et al. Among authors: la rosa c. ERJ Open Res. 2020 Nov 2;6(4):00284-2020. doi: 10.1183/23120541.00284-2020. eCollection 2020 Oct. ERJ Open Res. 2020. PMID: 33263037 Free PMC article.
267 results